A revolution of in vitro culture for drug discovery.
At Mirimus, we are dedicated to advancing the field of diagnostic testing through innovative and scalable solutions. Our expertise spans the development of Laboratory Developed Tests (LDTs) and comprehensive pathogen testing, enabling us to deliver rapid, reliable results for a wide array of diagnostic needs. With a commitment to excellence, we provide high-quality diagnostic testing services that are critical for healthcare providers, public health efforts, and personalized medicine.
Our track record includes a significant contribution during the height of the COVID-19 pandemic, when we played a pivotal role in supporting the health and safety of New York City through extensive testing services. Our innovation in developing rapid COVID-19 testing solutions earned us the prestigious X Prize for Innovation, underscoring our leadership in public health and diagnostic excellence.
As a recognized leader in COVID-19 testing, Mirimus offers comprehensive services that range from high-throughput screening to rapid diagnostic assays. Our COVID-19 testing solutions are designed to meet a variety of needs, from large-scale public health efforts to individual diagnostic testing. During the pandemic, we played a critical role in providing extensive testing services, contributing to the health and safety of communities. Our COVID-19 testing services include:
Our multiplex testing platform allows for the simultaneous detection of multiple respiratory pathogens, including Influenza (Flu), COVID-19, and Respiratory Syncytial Virus (RSV). This comprehensive approach reduces diagnostic turnaround time and provides healthcare providers with critical information for managing respiratory infections. Key benefits include:
Mirimus provides fast and reliable MPOX (formerly known as monkeypox) testing to aid in the rapid identification and management of this pathogen. As part of our commitment to public health, we offer scalable testing solutions that can be deployed quickly during outbreaks or routine screenings. Our MPOX testing services include:
We offer advanced multiplex testing for the simultaneous detection of Chlamydia, Gonorrhea, Ureaplasma, and Mycoplasma, providing healthcare providers with a comprehensive view of sexually transmitted infections (STIs) in a single assay. Our multiplex STI testing offers:
Mirimus is equipped to handle diagnostic testing at scale, offering high-throughput testing solutions for public health programs, hospitals, universities, and large organizations. Our scalable infrastructure and automated testing platforms ensure that we can meet the demands of large-scale testing initiatives without compromising accuracy or turnaround times. Key features include:
Mirimus is at the cutting edge of diagnostic testing, offering innovative and scalable solutions to meet diverse needs. Our state-of-the-art technology and experienced team allow us to provide accurate, fast, and reliable testing services across a broad range of diagnostic challenges. We prioritize:
Our award-winning testing solutions, such as our rapid COVID-19 tests, demonstrate our ability to lead the field in diagnostic innovation.
With high-throughput testing capabilities, we can handle both individual diagnostic needs and large-scale public health initiatives.
Our advanced molecular testing techniques ensure that every result is accurate and reliable, empowering healthcare providers to make informed decisions.
We remain committed to advancing public health through cutting-edge diagnostic testing, as demonstrated by our critical role during the COVID-19 pandemic.
Whether you need custom LDT development, rapid pathogen testing, or large-scale diagnostic solutions, Mirimus is your trusted partner. Contact us today to learn more about our diagnostic testing services and how we can support your diagnostic needs.
